Analytical Data
-
基因名
Mesothelin
-
简介
Mesothelin Protein, especially in its membrane-anchored forms, potentially mediates cellular adhesion, implicating its role in cell interactions. Furthermore, the associated Megakaryocyte-potentiating factor (MPF) actively enhances in vitro megakaryocyte colony formation, indicating its participation in fostering specialized blood cell colonies' development. Mesothelin Protein, Human (112a.a, Biotinylated, HEK293, His, Avi) is the recombinant human-derived Mesothelin protein, expressed by HEK293, with C-Avi and C-His labeled tag.
- Application
-
别名
MSLN; CAK1; Mesothelin; MPF; MPFSMRP; SMR
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q13421-3
-
表达区间
M487-S598
-
蛋白长度
Partial
-
分子量
20-40 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Mesothelin is a glycoprotein that is primarily expressed in mesothelial tissues and is associated with various cancers, including mesothelioma, pancreatic cancer, and ovarian cancer. Its overexpression in malignant cells makes mesothelin an attractive target for cancer immunotherapy and diagnostic applications. Research on mesothelin-recombinant proteins has gained traction due to its potential role as a biomarker and therapeutic target. Recombinant mesothelin can be produced using recombinant DNA technology, allowing for high yields and purity. Studies have demonstrated that targeting mesothelin with monoclonal antibodies or engineered T cells can effectively induce tumor cell apoptosis and inhibit cancer progression in preclinical models. Additionally, mesothelin-based vaccines are being explored to elicit a strong immune response against mesothelin-expressing tumors. The ongoing development and optimization of mesothelin-targeted therapies could provide significant advancements in the treatment of mesothelin-positive cancers, offering hope for improved patient outcomes in aggressive malignancies.
